July 14, 2011
Continuity as Debiopharm Group(TM) Management Moves Forward
LAUSANNE, Switzerland, July 14, 2011 /PRNewswire/ --
Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical
group of companies with a focus on the development of innovative therapies,
primarily in oncology, has appointed a number of management figures to key
positions, which will help ensure the perennial success of the group over
the long term.
same level of financial rigor and corporate governance as companies listed
on the stock market. It is for this reason that Debiopharm has created a
Strategy Committee, which will adopt recommendations in respect of the
overall direction of the group, and a Development Committee, which will be
tasked with optimising the development stages of Debiopharm's products. Dr
Kamel Besseghir, who joined Debiopharm in 1995 and has been successfully
heading Debiopharm S.A. as CEO since 2006, will chair both committees,
starting January 1, 2012.
From that same date he will be succeeded as CEO of Debiopharm S.A. by Dr
Bertrand Ducrey, currently CEO of Debio R.P. (Martigny). Bertrand Ducrey has
a Ph.D. in Pharmaceutical Sciences and was appointed general manager of
Debio R.P. in 2004 before being appointed CEO in 2006. Under Dr Ducrey's
leadership, Debio R.P.'s achievements have significantly contributed to the
success of Debiopharm Group(TM).
Dr Ducrey's current responsibilities as chief executive at Debio R.P.
will be taken over by Dr Cedric Sager, who will be promoted to the position
of CEO effective January 1, 2012. Dr Sager joined Debio R.P. after having
obtained his Ph.D. in Peptide Chemistry in 2001. He held various positions
within the company before being appointed Manufacturing Director in 2004 and
has assisted the CEO with various responsibilities since 2007.
We thank our three colleagues for what they have achieved to date and we
wish them all the very best in what they will continue to achieve in their
respective careers with Debiopharm Group(TM).
These appointments will enable the group to continue to make the best
possible use of the leadership abilities of the individuals concerned and,
at the same time, demonstrate the group's determination to move forward
while ensuring continuity and stability.
"One of the main tasks of the individuals we have appointed to these key
positions will be to put in place Debiopharm's flagship project to bring
down costs and reduce the development period of our drugs whilst maintaining
our extremely rigorous standards in respect of quality," said Dr
Rolland-Yves Mauvernay, founder and President of Debiopharm Group(TM).
Thierry Mauvernay, Executive Vice-President of Debiopharm Group(TM) said:
"With these appointments, Debiopharm Group(TM) is even better equipped to
face the major challenge in our industry, that of making available to
healthcare systems drugs that allow the treatment of more patients, better
and at a lesser cost."
About Debiopharm Group(TM)
Debiopharm Group(TM) is a Swiss-based global biopharmaceutical group of
companies with a focus on the development of prescription drugs that target
unmet medical needs, particularly in oncology.The group in-licenses,
develops and/or co-develops promising biological and small molecule drug
candidates having reached clinical development phases I, II or III aswell as
earlier stage candidates.It develops its products for global registration
and maximum commercial potential. The products are out-licensed to
pharmaceutical partners for sales and marketing. Debiopharm Group(TM) is also
active in the field of companion diagnostics with a view to progressing in
the area of personalised medicine.Debiopharm independently funds the
worldwide development of all its products while providing expertise in
pre-clinical and clinical trials, manufacturing, drug delivery and
formulation, and regulatory affairs.For more information on Debiopharm
Group(TM), please visit: http://www.debiopharm.com
Contact Debiopharm S.A. Maurice Wagner, Ph.D. Director Corporate Affairs & Communication Tel.:+41(0)21-321-01-11 E-mail: [email protected]
SOURCE The Debiopharm Group